OptiNose, Inc. (OPTN) DCF Valuation

OptiNose, Inc. (OPTN) DCF Valuation
  • ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
  • ✓ Design Profissional: Modelos Confiáveis ​​E Padrão Da Indústria
  • ✓ Pré-Construídos Para Uso Rápido E Eficiente
  • ✓ Não É Necessária Experiência; Fácil De Seguir

OptiNose, Inc. (OPTN) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Looking to assess the intrinsic value of OptiNose, Inc.? Our OPTN DCF Calculator integrates real-world data with extensive customization features, enabling you to refine forecasts and enhance your investment choices.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 34.6 49.1 74.7 76.3 71.0 86.8 106.1 129.7 158.6 193.9
Revenue Growth, % 0 41.83 51.99 2.18 -6.93 22.26 22.26 22.26 22.26 22.26
EBITDA -99.3 -85.3 -65.7 -57.5 -15.6 -66.9 -81.8 -100.0 -122.2 -149.4
EBITDA, % -286.81 -173.71 -87.98 -75.33 -21.91 -77.04 -77.04 -77.04 -77.04 -77.04
Depreciation 1.1 1.5 .6 .5 .4 1.4 1.8 2.1 2.6 3.2
Depreciation, % 3.19 2.96 0.86401 0.69747 0.5663 1.66 1.66 1.66 1.66 1.66
EBIT -100.4 -86.8 -66.3 -58.0 -16.0 -67.2 -82.2 -100.5 -122.9 -150.2
EBIT, % -290 -176.67 -88.84 -76.03 -22.48 -77.47 -77.47 -77.47 -77.47 -77.47
Total Cash 147.1 144.2 110.5 94.2 73.7 86.8 106.1 129.7 158.6 193.9
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 13.6 23.4 35.4 33.9 19.9
Account Receivables, % 39.4 47.63 47.49 44.49 28.07
Inventories 3.5 9.0 11.8 9.4 8.1 11.8 14.4 17.7 21.6 26.4
Inventories, % 10.06 18.41 15.87 12.38 11.34 13.61 13.61 13.61 13.61 13.61
Accounts Payable 3.6 5.5 8.0 5.3 3.9 7.8 9.5 11.6 14.2 17.4
Accounts Payable, % 10.47 11.18 10.73 6.94 5.47 8.96 8.96 8.96 8.96 8.96
Capital Expenditure -.6 -.5 -.2 -.1 -.3 -.6 -.7 -.9 -1.1 -1.4
Capital Expenditure, % -1.61 -1.11 -0.2237 -0.08259479 -0.46206 -0.69767 -0.69767 -0.69767 -0.69767 -0.69767
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -99.4 -85.5 -65.8 -59.2 -16.0 -66.8 -81.7 -99.9 -122.1 -149.3
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -112.4 -98.0 -77.7 -57.5 -1.9 -81.9 -89.6 -109.5 -133.9 -163.7
WACC, % 12.35 12.3 12.38 12.46 12.46 12.39 12.39 12.39 12.39 12.39
PV UFCF
SUM PV UFCF -396.0
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -167
Terminal Value -1,607
Present Terminal Value -896
Enterprise Value -1,292
Net Debt 58
Equity Value -1,350
Diluted Shares Outstanding, MM 112
Equity Value Per Share -12.05

What You Will Get

  • Real OptiNose Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for OptiNose, Inc. (OPTN).
  • Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates specific to OptiNose, Inc. (OPTN).
  • Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on OptiNose, Inc.'s (OPTN) fair value.
  • Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections for OptiNose, Inc. (OPTN).
  • Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility for OptiNose, Inc. (OPTN).

Key Features

  • Comprehensive OPTN Data: Pre-populated with OptiNose’s historical performance metrics and future growth estimates.
  • Customizable Assumptions: Modify key factors such as revenue growth, profit margins, discount rates, tax implications, and capital investments.
  • Interactive Valuation Framework: Real-time adjustments to Net Present Value (NPV) and intrinsic value based on user-defined parameters.
  • What-If Analysis: Develop various forecasting scenarios to explore a range of valuation possibilities.
  • Intuitive Interface: Clean, organized layout designed for both seasoned professionals and newcomers.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered OptiNose data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for OptiNose’s intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose OptiNose, Inc. (OPTN)?

  • Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs.
  • Proven Efficacy: Clinical trials demonstrate the effectiveness of our products in improving patient outcomes.
  • Commitment to Quality: Rigorous standards ensure the highest quality in our manufacturing processes.
  • Patient-Centric Approach: Focused on enhancing the patient experience through user-friendly delivery systems.
  • Backed by Research: Strong scientific foundation supported by ongoing research and development.

Who Should Use OptiNose, Inc. (OPTN)?

  • Healthcare Investors: Make informed investment choices with comprehensive market analysis tools.
  • Pharmaceutical Analysts: Streamline your assessments with pre-built financial models tailored for the biotech sector.
  • Medical Consultants: Efficiently modify templates for client proposals or industry reports.
  • Biotech Enthusiasts: Enhance your knowledge of drug development processes through real-world case studies.
  • Educators and Students: Utilize it as a hands-on resource in courses related to healthcare finance and biotechnology.

What the Template Contains

  • Preloaded OPTN Data: Historical and projected financial data, encompassing revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Advanced sheets designed for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for modifying revenue growth, tax rates, and discount rates.
  • Financial Statements: Detailed annual and quarterly financials for in-depth analysis.
  • Key Ratios: Metrics on profitability, leverage, and efficiency to assess performance.
  • Dashboard and Charts: Visual representations of valuation outcomes and underlying assumptions.

No products were found matching.